Bharat Biotech and Ocugen to bring Covaxin in US and Canada
Ocugen intends to continue working with FDA to evaluate regulatory pathways for the pediatric use of Covaxin.
New Delhi: Bharat Biotech a pioneering biotechnology company, on Monday said it, along with its partner Ocugen, is fully committed to bringing COVID-19 vaccine Covaxin in the US and Canada for all age groups. In a statement issued on Twitter, the Hyderabad-based vaccine major said Ocugen's Phase 2/3 Investigational Drug Application for Covaxin has been recently cleared by the US Food and Drug Administration(USFDA) for conducting clinical trials in adults.
Bharat Biotech is a pioneering biotechnology company. The company is known for its R&D and manufacturing capabilities. The company's mission is to deliver affordable, safe and high-quality vaccines and bio-therapeutics that help people prevail over diseases. The company seeks to lead innovation in biotechnology in order to lead the fight against disease with a focus on emerging markets.
Read Also - Bharat Biotech grants Rs 172 crore royalty to ICMR from Covaxin sale
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd